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Abstract 
Background: Type 1 diabetes mellitus (T1DM) patients display increased risk of cardiovascular disease (CVD) and are 
characterized by a diminished regulatory T (Treg) cell content or function. Previous studies have shown an association 
between decreased CDKN2A/2B/2BAS gene expression and enhanced CVD. In the present study the potential relation‑
ship between CDKN2A/2B/2BAS gene expression, immune cell dysfunction and increased cardiovascular risk in T1DM 
patients was explored.
Methods: A cross‑sectional study was performed in 90 subjects divided into controls and T1DM patients. Circulating 
leukocyte subpopulations analysis by flow cytometry, expression studies on peripheral blood mononuclear cell by 
qPCR and western blot and correlation studies were performed in both groups of subjects.
Results: Analysis indicated that, consistent with the described T cell dysfunction, T1DM subjects showed decreased 
circulating CD4+CD25+CD127− Treg cells. In addition, T1DM subjects had lower mRNA levels of the transcrip‑
tion factors FOXP3 and RORC and lower levels of IL2 and IL6 which are involved in Treg and Th17 cell differentiation, 
respectively. T1DM patients also exhibited decreased mRNA levels of CDKN2A (variant 1 p16Ink4a), CDKN2A (p14Arf, 
variant 4), CDKN2B (p15Ink4b) and CDKN2BAS compared with controls. Notably, T1DM patients had augmented pro‑
atherogenic CD14++CD16+‑monocytes, which predict cardiovascular acute events and enhanced common carotid 
intima‑media thickness (CC‑IMT).
Conclusions: Decreased expression of CDKN2A/2B/2BAS in leukocytes associates with increased CC‑IMT atheroscle‑
rosis surrogate marker and proatherogenic CD14++CD16+ monocytes in T1DM patients. These results suggest a 
potential role of CDKN2A/2B/2BAS genes in CVD risk in T1DM.
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Background
Type 1 diabetes mellitus is an autoimmune disease 
characterized by a deficiency of insulin production 
by the pancreas. Increased susceptibility to T1DM is 
determined by a combination of several genetic and 
environmental factors. Thus, variants of human leu-
kocyte antigen (HLA) genes which influences antigen 
presentation during thymic cell selection processes 
and peripheral activation of the immune response have 
been associated with T1DM pathogenesis [1]. The dis-
ease results from the destruction of insulin-producing β 
cells by autoreactive effector CD4+ and CD8+ T cells, 
which initially infiltrate the islets producing insulitis, 
in response to pancreatic islet autoantigens [2]. These 
autoreactive T cell responses to autoantigens are pre-
sent before the clinical onset of the disease. In healthy 
conditions T cell responses are balanced by regulatory 
mechanisms such as immunological tolerance, but have 
a reduced functional capacity during disease develop-
ment [1]. One key player in immunological tolerance 
is a CD4+ T cell sub-population, regulatory T (Treg) 
cells, whose defective function has been suggested to 
contribute to T1DM development. It has been shown 
that T1DM individuals display apoptosis-prone Treg 
cells in the blood. Furthermore, analysis of lymphocytic 
islet infiltration from T1DM patient donors revealed 
autoreactive T cells with an effector phenotype, such as 
CD4+ T helper (Th) 1, an abnormal expansion of pro-
inflammatory effector Th17 cells and diminished Treg 
cell content or function [3].
Despite glycemic control through restoration of insulin 
levels, T1DM subjects display increased cardiovascular 
disease (CVD) similar to that observed in type 2 diabetes 
mellitus (T2DM) subjects [4, 5]. However, unlike T2DM 
there is a lack of understanding of the risk in T1DM 
patients in current intensive glycemic control manage-
ment guidelines. Many T1DM patients might display 
metabolic abnormalities that promote characteristics 
associated with enhanced CVD risk such as a chronic 
proinflammatory state. On the other hand, as mentioned 
above, T1DM subjects exhibit deranged T cell function 
which is also associated with increased CVD risk.
In fact, atherosclerosis progression, the main cause of 
CVD, is facilitated by an unbalanced interplay of differ-
ent CD4+ T cell subsets, which promote plaque lesion 
formation in the vascular bed. Proinflammatory effector 
CD4+ Th1 and Th17 subsets are proatherogenic while 
Treg cells, which are a minor population in plaques, 
suppress Th cell activity in lesions. Moreover, Treg cells 
promote an anti-inflammatory and pro-resolving mac-
rophage phenotype within atheromas [6]. Thus, altered 
Treg/Th17 ratio in circulating leukocytes favor athero-
sclerosis progression and human patients with vulnerable 
atheroma plaques and coronary artery disease (CAD) 
display reduced circulating Treg cells [7–9].
We have recently shown that CAD complications in 
T2DM subjects associated with changes in immune 
cell homeostasis and with diminished expression of 
CDKN2A/2B/2BAS genes [10]. These genes encode for 
the tumour suppressors  p16Ink4a, ARF and  p15Ink4b and 
the regulatory antisense non-coding RNA named ANRIL 
(antisense noncoding RNA in the INK4 locus) [11]. Pre-
vious genome-wide studies linked single nucleotide 
polymorphisms (SNPs) in CDKN2A/2B/2BAS genes to 
increased risk of T2DM and CVD [11]. Functional stud-
ies also indicated that upregulation of these genes might 
be a therapeutic tool to modulate insulin resistance and 
atherosclerosis [12–17].
In light of the above research, in the present study 
we investigated whether deranged immune systems 
in T1DM individuals could be related to atheroscle-




The study was performed in accordance with the ethical 
principles of the Helsinki Declaration, and was approved 
by the Hospital Clínico Universitario de Valencia ethics 
committee. All subjects gave written informed consent. 
For the study 90 unrelated individuals attending the out-
patient clinic and selected over 18 months by the oppor-
tunistic sampling method, were divided into controls 
and T1DM subjects. T1DM was diagnosed when fast-
ing plasma glucose was ≥ 126  mg/dL or when HbA1C 
was ≥ 6.5% or when a patient had classic symptoms of 
hyperglycemia or hyperglycemic crisis, with a random 
plasma glucose ≥ 200  mg/dl, in accordance with the 
ADA criteria for T1DM [18] together with positivity of 
autoantibodies.
Human carotid artery ultrasound evaluation for common 
carotid intima‑media thickness (CC‑IMT)
A standardized imaging protocol was used for common 
carotid intima-media thickness (CC-IMT) measure-
ments in agreement with the Mannheim consensus [19]. 
B-mode ultrasound imaging of the right and left carotid 
arteries was performed using a Siemens Sonoline G40 
instrument equipped with 7 to 10-MHz broadband lin-
ear array transducers as previously described [20]. With 
the carotid dilatation and flow dividers as anatomic 
landmarks, the sonographer obtained high-resolution 
images of the common carotid (1  cm proximal to the 
bifurcation), the bifurcation (between dilatation and 
flow divider), and the internal carotid (1  cm distal to 
the flow divider). Carotid arteries and bifurcation were 
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examined for presence of atherosclerotic plaques defined 
as described [20]. An experienced sonographer (S.M.-H.) 
performed all examinations. Intraobserver variability was 
examined in 20 subjects. The coefficient of variability of 
mean CC-IMT was 5.2%.
Human plasma parameters analysis and enzyme‑linked 
immunosorbent assay (ELISA)
Samples were collected after 12–14  h fasting from an 
antecubital vein in tubes containing EDTA (BD Vacu-
tainer) and centrifuged within 4  h. Plasma was stored 
at 4  °C and biochemical parameters were measured by 
standard clinical methodology. Insulin was determined 
by radioimmunoassay. For ELISA heparinized human 
whole blood (10 U heparin/ml) was obtained, plasma was 
isolated and cytokines were measured using the human 
MCP1, TNFα, TGFβ, IL2, IL6 and IL17 DuoSet ELISA 
(R&D Systems, UK).
Gene expression analysis by quantitative real‑time PCR 
(qPCR)
Human peripheral blood mononuclear cells (PBMCs) 
were isolated from whole blood of patients with Lym-
phoprep (Axis Shield PoC, Norway) to obtain RNA using 
TRIzol (Invitrogen). RNA (0.5-1 μg) was retrotranscribed 
with cDNA Synthesis kit and amplified with Luminars 
Color-qPCR Master MIX (Fermentas) using a thermal 
Cycler 7900Fast System (Applied Biosystems). The prim-
ers were (Forward: Fw; Reverse: Rv): human CDKN2A 
(splice variant 4, p14Arf): Fw 5′CCC TCG TGC TGA TGC 
TAC TG3′ and Rv 5′CAT CAT GAC CTG GTC TTC TAG 
GAA 3′; human CDKN2A (splice variant 1, p16Ink4a): Fw 
5′GGG GGC ACC AGA GGC AGT 3′ and Rv 5′ GGT TGT 
GGC GGG GGC AGT T3′; human CDKN2B (p15Ink4b): Fw 
5′GGC AGT CGA TGC GTT CAC T3′ and Rv 5′AGG GCC 
TAA GTT GTG GGT TCA3′; human CDKN2BAS: Fw 
5′CAT GGT GGC AGC AAG AGA AAA3′ and Rv 5′TGA 
TGG GTT TAT CAG AGG TTTCC3′; human GAPDH: Fw 
5′ACC ACA GTC CAT GCC ATC AC3′ and Rv 5′TCC ACC 
ACC CTG TTG CTG TA3′; human FOXP3: Fw 5′GTG 
GCC CGG ATG TGA GAA G3′ and Rv 5′GGA GCC CTT 
GTC GGA TGA TG3′; human GATA3: Fw 5′TTA GAG 
CCC TGC TCG ATG CT3′ and Rv 5′CAT GAT ACT GCT 
CCT GCA AAA ATG 3′; human TBET: Fw 5′TGC TCC 
AGT CCC TCC ATA AGTAC3′ and Rv 5′TCT GGC TCT 
CCG TCG TTC AC3′; human RORC: Fw 5′GAA GTG GTG 
CTG GTT AGG ATGTG3′ and Rv 5′CCA CCG TAT TTG 
CCT TCA AAA3′; human SOCS1: Fw 5′CCC TGG TTG 
TTG TAG CAG CTT3′ and Rv 5′GGT TTG TGC AAA GAT 
ACT GGG TAT ATG3′; human SOCS3: Fw 5′TGG GAC 
GAT AGC AAC CAC AA3′ and Rv 5′CGA AGT GTC CCC 
TGT TTG GA3′. Results were analyzed with the pro-
vided software. mRNA levels were normalized with the 
endogenous control and with the relativized to control 
group mRNA levels.
Western blot analysis
Human PBMC pellets were homogenized in the presence 
of ice-cold lysis TNG buffer (Tris–HCl 50  mM, pH7.5, 
NaCl 200 mM, Tween-20 1%, NP-40 0.2%) supplemented 
with protease inhibitor Complete Mini cocktail, PhosS-
TOP Phosphatase Inhibitor Cocktail (Roche, Germany), 
2  Mm PhenylMethylSulfonylFluorid (PMSF), ß-glycerol 
phosphate 50 mM and 200 µM Na3VO (Sigma). Protein 
extracts (35-50  µg) were prepared with Laemmli buffer 
(5 min, 95 °C) and subjected to 12% w/v polyacrylamide 
gel electrophoresis and western blot analysis as described 
[10]. The following primary and secondary antibod-
ies were used: anti-CDK4 (sc-260, SantaCruz), anti-p21 
(sc-397 SantaCruz), anti-p27 (610242, BD), anti-β-Actin 
(A5441, Sigma), anti-mouse IgG-HRP (sc-2005, San-
taCruz) and anti-rabbit IgG-HRP (sc-2004, SantaCruz). 
The immunocomplexes were detected with ECL Plus 
(ThermoFisher).
Flow cytometry measurements
To characterize leukocytes 10  µl of heparinized whole 
blood from human samples cells were incubated (30 min, 
RT) with anti-CD3-APC, anti-CD69-PE, anti-CD14-
V450, anti-CD16-PerCP-Cy5.5 and Regulatory T cell 
Cocktail (all from BD Pharmigen). All stainings were fol-
lowed by incubation with Facs Lysing solution (BD) for 
15-20  min before flow cytometry analysis using FACS-
Verse Flow cytometers (BD Biosciences, USA).
Statistical analysis
Quantitative variables appear as mean ± sem and corre-
lations as individual points. Differences were assessed by 
Student´s t-test or Mann–Whitney U test and correlation 
studies by the Spearman correlation coefficient (Graph-
Pad Prism 5.03, CA, USA). Statistical significance was set 
at p ≤ 0.05.
Results
Characterization of human subjects with T1DM 
and controls
Patients’ demographic and clinical characteristics are 
summarized in Table  1. Gender and age distribution 
were similar between T1DM and control groups. Com-
pared with controls, T1DM had higher levels of systolic 
blood pressure (p < 0.05), BMI index (p < 0.01), fasting 
glucose (p < 0.001), HbA1c (p < 0.001) and lower levels 
of HDL-C (p < 0.05). No differences between the two 
groups were observed in total-cholesterol (CT), LDL-
cholesterol, apoB or in triglycerides. Compared with 
controls, T1DM also displayed augmented CC-IMT, 
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the surrogate atherosclerotic marker, (p < 0.03) indicat-
ing increased CVD risk. T1DM subjects had a higher 
prevalence (19.35% vs 0%) of statin treatment, as lipid-
lowering therapy, than controls.
As expected CC-IMT positively correlated with age 
(p < 0.03), BMI (p < 0.04), HbAc1 (p < 0.02), glucose 
(p < 0.01), LDL-C (p < 0.03) and apoB levels (p < 0.02) 
(Additional file 1: Table S1).
Circulating leukocyte characterization in T1DM and control 
human subjects
Leukocyte analysis revealed no differences in the per-
centage of total lymphocytes, monocytes or neutro-
phils (Fig.  1a). Likewise, no differences were observed 
in the levels of total CD3 + T or activated CD3+ 
CD69+ T-lymphocytes between controls and T1DM 
patients (Fig.  1b). However, the percentage of CD4+ 
CD25+ CD127− Treg cells was significantly reduced in 
T1DM compared with controls (Fig. 1c, p < 0.02) with-
out changes in total CD4+ T cells. Analysis of circu-
lating monocytes into classical CD14++, intermediate 
CD14++ CD16+ and non-classical CD14+CD16++ 
subsets [21, 22], demonstrated an increase in the proin-
flammatory CD14++CD16+ subpopulation in T1DM 
patients compared with controls (Fig. 1d, p < 0.03).
CDKN2A/2B/2BAS gene expression levels are altered 
in human subjects exhibiting T1DM
Expression analysis in PBMCs showed lower mRNA 
levels of the CDKN2A (splice variant 1, p16Ink4a), 
of CDKN2A (splice variant 4, p14Arf), and CDKN2B 
(p15Ink4b), CDKN2BAS genes in T1DM individuals 
compared with controls (Fig.  2a, CDKN2A (p16Ink4a), 
p < 0.02; CDKN2A (p14Arf) p < 0.04; CDKN2B (p15Ink4b) 
p < 0.03; CDKN2BAS p < 0.03). Analysis of other cell-
cycle-related inhibitors showed decreased levels of 
p21 (p < 0.02) in T1DM individuals (Fig. 2d) compared 
with controls and no changes in CDK4 or p27 proteins 
(Fig. 2b, c).
Correlation studies of CDKN2A/2B/2BAS gene showed 
a negative correlation of CDKN2A (p16Ink4a) mRNA 
expression with HbA1C levels (Table  2, p < 0.05). Simi-
larly, a negative correlation was found between CDKN2B 
(p15Ink4b) mRNA expression and glucose levels (Table 2, 
p < 0.03).
Altered T cell subsets in PBMCs from human T1DM patients
T1DM is characterized by deranged balance of CD4+ 
Th cellular subsets, whose fate is determined by the 
expression of their corresponding transcription factors 
and activation of the different cytokine-induced JAK/
STAT(signal transducer and activator of transcription)-
signaling pathways. Expression of the above were there-
fore analyzed in T1DM subjects and controls.
Expression analysis showed a marked reduction in 
FOXP3 expression, a key transcription factor for Treg 
cell function, in T1DM subjects compared with controls 
(Fig. 3d, p < 0.0001). Similarly, analysis of the mRNA lev-
els of RORC, the transcription factor expressed in Th17 
cells was also diminished in T1DM subjects (Fig.  3c, 
p < 0.02). No changes were observed in TBET or GATA3 
(Fig.  3a, b). Given that JAK-dependent pathways can 
be directly inhibited by SOCS1 and SOCS3 proteins 
[23], these were also analyzed. T1DM patients showed 
a marked decrease in the expression of SOCS1 mRNA 
(Fig. 3e, p < 0.007) and no changes in SOCS3 mRNA lev-
els (Fig. 3f ) compared with controls.
Inverse correlations were found between mRNA levels 
of FOXP3 and SOCS1 and HbA1c   % (Additional file  1: 
Table  S2 p < 0.007 and p = 0.05 respectively) as well as 
with glucose levels (Additional file  1: Table  S2, p < 0.05 
and p < 0.004, respectively).
Circulating cytokine plasma analysis showed no 
changes in MCP1, TNFα or TGFβ levels between T1DM 
patients and controls (Fig.  4a, b). IL2 and IL6 were sig-
nificantly decreased in T1DM compared with controls 
(Fig. 4d, e, p < 0.05 both) and no changes were observed 
in IL17 between controls and T1DM (Fig. 4f ).
Table 1 Demographic and  clinical characteristics 
of human subjects
SBP systolic blood pressure, DBP diastolic blood pressure, BMI body mass index, 
LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein 
cholesterol, apoB apolipoprotein B, CC-IMT common carotid intima‑media 
thickness
* p < 0.05; ** p < 0.01; *** p < 0.001. Statistical significance was assessed by 
Mann–Whitney U test
Controls (n = 48) T1DM (n = 29)
Age (years) 32.3 ± 1.4 32.5 ± 1.7
SBP (mmHg) 116.2 ± 1.8 136.0 ± 1.8*
DBP (mmHg) 73.2 ± 1.1 74.2 ± 1.3
Glucose (mg/dL) 87.7 ± 1.6 160.3 ± 13.6***
HbA1c (%) 5.3 ± 0.1 7.6 ± 0.2***
BMI 23.3 ± 0.6 25.5 ± 0.5
Total cholesterol (mg/dL) 182.2 ± 4.1 175.7 ± 5.4
HDL‑C (mg/dL) 61.46 ± 1.7 56.8 ± 1.5
LDL‑C (mg/dL) 116.12 ± 3.2 114.3 ± 4.5
apoB (mg/dL) 84.88 ± 2.7 84.77 ± 3.4
Triglycerides (mg/dL) 75.9 ± 4.3 67.7 ± 4.7
CC‑IMT (mm) 0.41 ± 0.01 0.46 ± 0.01**
% of lipid‑lowering therapies 
(statins)
0 19.35***























































































































































Fig. 1 Characterization of circulating leukocytes in control and T1DM individuals. a Analysis of circulating lymphocytes, monocytes and neutrophils 
in both groups of subjects. b Circulating levels of CD3+ and CD3+CD69+ T‑lymphocytes. c Circulating percentages of CD4 + T and CD4+ 
CD25+CD127−Treg cells. d Percentages of CD14 ++CD16‑, CD14++CD16+ and CD14+ CD16++ monocytes relative to total monocytes. 
Statistical analysis was performed using Student’s t‑test
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Moreover, mRNA levels of CDKN2A  (p16Ink4a) posi-
tively correlated with FOXP3 levels (Fig.  5a, p < 0.002) 
while CDKN2B mRNA levels correlated with RORC 
(p < 0.001) mRNA levels (Fig. 5c). CDKN2A  (p14Arf) and 
CDKN2BAS mRNA levels correlated with both RORC 
(p < 0.002 and p < 0.0001, respectively) and FOXP3 
(p < 0.0001 and p < 0.005) mRNA levels (Fig. 5b, d). On 
the other hand, SOCS1 mRNA levels positively corre-
lated with the mRNA expression of CDKN2A (p14Arf), 
CDKN2B (p15Ink4b) and CDKN2BAS (Fig.  6a, p < 0.03, 
p < 0.0001 and p < 0.0003, respectively). SOCS3 mRNA 
levels correlated with CDKN2B (p15Ink4b) but not 
with the other gene mRNA expression levels (Fig.  6b 
p < 0.02).
Discussion
T1DM patients have an increased risk of CVD but the 
causes of this risk are not fully understood. In the pre-
sent study, we found diminished mRNA expression lev-
els of CDKN2A (p16Ink4a), CDKN2A (p14Arf), CDKN2B 
(p15Ink4b) and CDKN2BAS genes in circulating leuko-
cytes of T1DM patients, who also displayed increased 
atherosclerosis risk measured as CC-IMT. Consistent 
with the well-known deranged immune T-cell func-
tion, T1DM subjects exhibited lower circulating Treg 
(CD4+CD25+CD127−) cell percentages and reduced 
mRNA levels of transcription factors related to CD4+ 
Th differentiation, RORC and FOXP3, which are determi-












































































Fig. 2 Expression analysis in PBMCs from control and T1DM human subjects. a mRNA expression levels of CDKN2A(p16Ink4a), CDKN2A(p14Arf), 
CDKN2B and CDKN2BAS normalized with the endogenous GAPDH mRNA levels and relativized to control group levels. Protein expression of 
(b) CDK4, (c) p27 and (d) p21 in PBMCs from human controls and T1DM patients. Protein levels were normalized to β‑actin protein levels. 
Representative blots are shown below the quantifications. Statistical analysis was performed using Student’s t‑test
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agreement with lower expression of these transcription 
factors, IL2 and IL6 cytokine levels were also decreased in 
T1DM patients. Notably, T1DM subjects had enhanced 
percentages of the proinflammatory CD14++CD16+ 
monocyte subpopulation, a cellular subset that has 
been reported to predict acute cardiovascular events. 
Altogether, our study indicates an association between 
increased atherosclerosis in T1DM and reduced expres-
sion of CDKN2A/2B/2BAS in circulating leukocytes 
which displayed proatherogenic phenotypes such as 
enhanced proinflammatory monocytes and reduced Treg 
content. Therefore, the present data suggest for the first 
time a potential role of CDKN2A/2B/2BAS through a 
decreased expression in leukocytes in atherosclerosis 
Table 2 Correlation between HbA1C and glucose levels and mRNA expression levels of the indicated genes
* p < 0.05; Statistical significance was assessed by non‑parametric Spearman correlation coefficient
HbA1C
Rho spearman p value
CDKN2A (p16Ink4a) − 0.2721 0.0445*
CDKN2A (p14Arf) − 0.2045 0.1341
CDKN2B (p15Ink4b) − 0.2324 0.074
CDKN2BAS − 0.1738 0.1843
Glucose
Rho spearman p value
CDKN2A (p16Ink4a) − 0.0929 0.4919
CDKN2A (p14Arf) − 0.0526 0.6973
CDKN2B (p15Ink4b) − 0.2802 0.0274*











































































Fig. 3 Analysis of the CD4 + T‑cell differentiation signaling pathways in PBMCs from control and T1DM human subjects. mRNA expression levels 
of TBET (a), GATA3 (b), RORC (c), FOXP3 (d), SOCS1 (e) and SOCS3 (f). mRNA levels were normalized with the endogenous GAPDH mRNA levels and 
relativized to control group levels. Statistical analysis was performed using Student’s t‑test
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risk and development in T1DM, which could facilitate a 
pro-atherogenic profile in these cells by generating pro-
inflammatory monocytes and lower content of Treg cell 
content.
Former studies have shown an increased CVD risk in 
T1DM patients despite intensive glycemic control [4]. 
However, ours is the first investigation that associates 
this CVD risk with a markedly reduced expression of 
CDKN2A/2B/2BAS genes in circulating leukocytes from 
T1DM patients. Previous genome-wide studies have 
linked SNPs in CDKN2A/2B/2BAS genes with enhanced 
risk of CVD and with T2DM [11]. In addition, functional 
human and murine studies have shown a protective role 
of these genes against metabolic diseases. An atheropro-
tective function has therefore been suggested for these 
genes, since genetic inactivation of Cdkn2a variants 
in mice increases atherosclerosis [12, 15] and reduced 
expression of the transcripts has been found in athero-
sclerosis patients [16]. Other studies suggested a role of 
these genes in carbohydrate metabolism [24], in insu-
lin secretion [14] and β-cell islet biology [25]. Enhanced 
expression of Cdkn2a/2b in mice also prevents insulin 
resistance associated with aging [13] and delays hepatic 
steatosis produced by insulin resistance [17]. In line with 
these investigations, our study indicates an association 
between diminished expression of CDKN2A/2B/2BAS 
genes in leukocytes and increased atherosclerosis risk in 
T1DM.
One limitation in our study is the higher frequency of 
statin use as lipid-lowering strategy which might exert 
anti-inflammatory actions [26]. However, the use of these 
did not interfere with the study as T1DM subjects dis-
played enhanced inflammatory status with increased pro-
inflammatory monocytes and decreased Treg cells.
In our study enhanced CC-IMT was also accompanied 
by augmented BMI and glucose levels and decreased cir-
culating HDL-C which is consistent with the well-known 
association between altered metabolism and CVD. 
These metabolic abnormalities could modify CVD risk 
in T1DM patients as seen in T2DM subjects. However, 
this risk could be further enhanced by the intrinsic dys-
regulation of T cells of T1DM subjects. T1DM is char-
acterized by impaired Treg function [27] and reduced 


















































































Fig. 4 Circulating cytokine levels in control and T1DM human subjects. Plasmatic circulating levels of a MCP1, b TNFα, c TGFβ, d IL2, e IL6 and f IL17. 
Statistical analysis was performed using Student’s t‑test
















































































Fig. 5 Correlation studies between of CDKN2A/2B/2BAS genes and transcription factors involved in T cell differentiation. Correlation of 
CDKN2A(p16Ink4a) a, CDKN2A(p14Arf) b, CDKN2B c, and CDKN2BAS d mRNA levels with RORC and FOXP3 mRNA levels. Statistical analysis was 





































































































































































Fig. 6 Correlation studies in all human subjects. Correlation of CDKN2A/2B/2BAS mRNA levels with a SOCS1 and b SOCS3 mRNA levels. Statistical 
analysis was performed using non‑parametric Spearman correlation coefficient
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coronary atherosclerosis, acute coronary syndromes and 
plaque rupture [8, 9]. Therefore, reduced circulating Treg 
cells in our T1DM subjects could reasonably contribute 
to increase atherosclerosis. On the other hand, deranged 
balance of CD4 + T cell subsets whose lineage commit-
ment is specified by cytokine environment and activation 
of their corresponding transcription factors [28] might 
also promote atherosclerosis [9, 29, 30]. T1DM patients 
exhibited decreased levels of IL2 and IL6 cytokine, which 
in the presence of TGFβ, promote Treg differentiation 
by inducing FOXP3 expression and Th17 differentia-
tion through RORC expression, respectively. FOXP3 and 
RORC were consistently diminished in leukocytes in our 
T1DM patients thus indicating reduced levels of Treg like 
before, as well as decreased Th17, whose role in athero-
sclerosis is controversial [30]. Moreover, SOCS1, which 
negatively regulates Treg but is necessary for its func-
tion [23] was also significantly reduced in T1DM sub-
jects. Besides modulation of self-tolerance, Treg cells 
promote an anti-inflammatory macrophage phenotype 
and cytokines [6], hence defective function or number 
of these could contribute to generate proinflammatory 
monocytes/macrophages. In fact, a major finding of our 
study is that increased atherosclerosis in T1DM was 
associated with a prevalence of circulating proinflam-
matory CD14++CD16+ monocytes which have been 
shown to predict cardiovascular events independently of 
other risk factors [21] and are associated with coronary 
plaque vulnerability in coronary disease patients [31]. 
We did not observe changes in the pro-inflammatory 
CD14++ monocytes which is consistent with another a 
study showing that CD14++CD16− monocytes do not 
associate with atherosclerosis measured as CC-IMT in 
subjects without CV acute events [32]. To our knowledge, 
this is the first study to indicate a relationship between 
CD14++CD16+ monocyte prevalence and atheroscle-
rosis in T1DM.
Pro-atherogenic and proinflammatory leukocyte 
phenotypes observed in T1DM subjects, although 
promoted by the autoimmune cell derangement char-
acteristic of these subjects, could be aggravated by the 
diminished expression of CDKN2A/2B/2BAS genes. 
Supporting this, a positive correlation was observed 
between CDKN2A/2B/2BAS expression and the tran-
scription factors FOXP3, RORC and SOCS3 mRNA 
levels in leukocytes, suggesting a potential relation-
ship between them. Furthermore, several lines of evi-
dences from previous research support a role of these 
genes in immune cell modulation. Thus, an anti-
inflammatory role has been attributed to Cdkn1a (vari-
ant 1,  p16Ink4a) by promoting IRAK1 degradation and 
diminishing cytokine secretion in macrophages [33]. 
Increased expression of Cdkn2a/2b genes in mouse 
models decreased circulating proinflammatory  Ly6Chi 
monocytes, reduced activated T cells and prevented 
macrophage infiltration into tissues [17]. Genetic inac-
tivation of Cdkn2a in the myeloid lineage enhanced 
 Ly6Chi-monocytes [15], promoted megakaryopoie-
sis and increased platelet activity [34]. Local infu-
sion of Cdkn2a (variant 1) in bone joints consistently 
impaired the expression of proinflammatory cytokines 
in a mouse model of autoimmune rheumatoid arthri-
tis [35]. Notably, we recently reported that coronary 
artery disease in T2DM (T2DM-CAD subjects) is 
accompanied by decreased Treg cells and diminished 
expression of CDKN2A/2B/2BAS [10]. Furthermore, 
treatment of human lymphocytes in  vitro and of ath-
erosclerotic mouse models in  vivo with PD0332991, a 
 p16Ink4a/p15Ink4b mimetic drug and a proven selective 
inhibitor of CDK4 (the main target of these proteins), 
augmented Treg levels and diminished atherosclerosis 
and vulnerable plaque in the mouse model [10]. Com-
parison of both investigations revealed a much lower 
CDKN2A/2B/2BAS gene expression in our former 
study in T2DM and T2DM with CAD compared with 
controls, which were up to 60-80% reductions while 
T1DM subjects displayed 40% reductions compared 
with controls. In addition, CV risk measured as CC-
IMT were 0.46, 0.594 and 0.829 for T1DM, T2DM and 
T2DM-CAD respectively which correlates well with 
reduced expression of CDKN2A/2B/2BAS genes and is 
consistent with the protective role of these genes. Alto-
gether, these findings suggest that CDKN2A/2B/2BAS 
gene modulation might modify inflammatory cell 
phenotype in diverse experimental settings. Hence, 
decreased expression of CDKN2A/2B/2BAS genes in 
the present study could potentially contribute to the 
altered leukocyte phenotype and promote atherosclero-
sis in T1DM subjects.
Conclusions
Our study shows for the first time that increased athero-
sclerosis risk in T1DM patients associates with decreased 
expression of CDKN2A/2B/2BAS in leukocytes, which 
display pro-atherogenic phenotypes consisting of 
reduced circulating Treg cells and augmented proinflam-
matory CD14++ CD16+ monocytes. Expansion and 
stabilization of Tregs have been cited as promising thera-
pies to treat both atherosclerosis [7] and autoimmune 
diseases such as T1DM [27]. Altogether, this suggests 
that therapies targeted at increasing CDKN2A/2B/2BAS 
to restore Treg cells, such as the ones we have previously 
described [10], could potentially be used to reduce CVD 
in T1DM patients.
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